Description

Perindopres (perindopril) tablets 8 mg. №30

Ingredients

Perindopres tablets contain 8 mg of perindopril as the active ingredient.

Dosage

The recommended dosage of Perindopres tablets is one 8 mg tablet taken orally once daily.

Indications

Perindopres tablets are indicated for the treatment of hypertension and heart failure.

Contraindications

Do not use Perindopres tablets if you are pregnant, have a history of angioedema related to previous ACE inhibitor therapy, or have severe renal impairment.

Directions

Take Perindopres tablets exactly as prescribed by your healthcare provider. Swallow the tablet whole with a glass of water.

Scientific Evidence

Perindopril, the active ingredient in Perindopres tablets, is an ACE inhibitor that works by inhibiting the angiotensin-converting enzyme, leading to vasodilation and reduced aldosterone secretion. Studies have shown that ACE inhibitors like perindopril are effective in reducing blood pressure and improving outcomes in patients with heart failure.

Additional Information

It is important to monitor blood pressure regularly while taking Perindopres tablets to ensure optimal control. Common side effects may include dizziness, cough, and hyperkalemia. Consult your doctor if you experience any adverse reactions.

Pharmacological Effects

Perindopril, as an ACE inhibitor, blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting this enzyme, perindopril helps dilate blood vessels, reduce blood pressure, and improve cardiac function. Additionally, it has been shown to have cardioprotective effects beyond its blood pressure-lowering properties.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of perindopril in reducing cardiovascular events and mortality in patients with heart failure and post-myocardial infarction. Compared to other ACE inhibitors, perindopril has shown similar efficacy but may have a more favorable side effect profile in certain patient populations.

References:
1. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-788.
2. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-1581.